The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis
Open accessAbstract
Although anecdotal reports suggest that cannabis may be used to alleviate symptoms of depression, the psychotropic effects and abuse liability of this drug prevent its therapeutic application. The active constituent of cannabis, Δ 9 -tetrahydrocannabinol, acts by binding to brain CB 1 cannabinoid receptors, but an alternative approach might be to develop agents that amplify the actions of endogenous cannabinoids by blocking their deactivation. Here, we show that URB597, a selective inhibitor of the enzyme fatty-acid amide hydrolase, which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide, exerts potent antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test. Moreover, URB597 increases firing activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in the nucleus locus ceruleus. These actions are prevented by the CB 1 antagonist rimonabant, are accompanied by increased brain anandamide levels, and are maintained upon repeated URB597 administration. Unlike direct CB 1 agonists, URB597 does not exert rewarding effects in the conditioned place preference test or produce generalization to the discriminative effects of Δ 9 -tetrahydrocannabinol in rats. The findings support a role for anandamide in mood regulation and point to fatty-acid amide hydrolase as a previously uncharacterized target for antidepressant drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
The Neuroendocrinology of Stress: A Never Ending Story
Lightman, S. L. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01711.x · Cited by 3,566
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Self-citationRole of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Self-citationModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Self-citationControl of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
Self-citationAn endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
Self-citationCurrent Protocols in Neuroscience
(2018) · Current Protocols in Neuroscience · doi:10.1002/(issn)1934-8576 · Cited by 767
Iversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732
Exploring the association between cannabis use and depression.
Degenhardt, L., Hall, W., & Lynskey, M. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00437.x · Cited by 587
Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., & Frank, R. A. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.4.322 · Cited by 481
Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Self-citationEndocannabinoid signaling system and brain reward: emphasis on dopamine
GARDNER, E. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.032 · Cited by 387
Page, M. E., Detke, M. J., Dalvi, A., Kirby, L. G., & Lucki, I. (1999) · Psychopharmacology · doi:10.1007/s002130051156 · Cited by 385
Navarro, M., Hernández, E., Muñoz, R. M., del Arco, I., Villanúa, M. A., Carrera, M. R. A., & Rodríguez de Fonseca, F. (1997) · NeuroReport · doi:10.1097/00001756-199701200-00023 · Cited by 306
Patel, S., Roelke, C. T., Rademacher, D. J., & Hillard, C. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03916.x · Cited by 297
Mor, M., Rivara, S., Lodola, A., Plazzi, P. V., Tarzia, G., Duranti, A., Tontini, A., Piersanti, G., Kathuria, S., & Piomelli, D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031140x · Cited by 276
Self-citationTherapeutic aspects of cannabis and cannabinoids
Robson, P. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.107 · Cited by 265
The search for the palmitoylethanolamide receptor
LoVerme, J., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.012 · Cited by 248
Self-citationHaller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241
The medicinal use of cannabis in the UK: results of a nationwide survey
Ware, M. A., Adams, H., & Guy, G. W. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2004.00271.x · Cited by 239
Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication
Volkow, N. D., Gillespie, H., Mullani, N., Tancredi, L., Grant, C., Valentine, A., & Hollister, L. (1996) · Psychiatry Research: Neuroimaging · doi:10.1016/0925-4927(96)02817-x · Cited by 219
Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors
Urigüen, L., Pérez-Rial, S., Ledent, C., Palomo, T., & Manzanares, J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.01.003 · Cited by 218
Cannabis use in HIV for pain and other medical symptoms
Woolridge, E., Barton, S., Samuel, J., Osorio, J., Dougherty, A., & Holdcroft, A. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.011 · Cited by 208
Solinas, M., Panlilio, L. V., Antoniou, K., Pappas, L. A., & Goldberg, S. R. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047928 · Cited by 194
Self-citationTarzia, G., Duranti, A., Tontini, A., Piersanti, G., Mor, M., Rivara, S., Plazzi, P. V., Park, C., Kathuria, S., & Piomelli, D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021119g · Cited by 165
Self-citationPatel, S., Cravatt, B. F., & Hillard, C. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300535 · Cited by 164
Patterns of Marijuana Use Among Patients With HIV/AIDS Followed in a Public Health Care Setting
Prentiss, D., Power, R., Balmas, G., Tzuang, G., & Israelski, D. M. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200401010-00005 · Cited by 147
Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers
Manji, H. K., Moore, G. J., & Chen, G. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.41.s107 · Cited by 138
Dual Monoamine Modulation for Improved Treatment of Major Depressive Disorder
Trân, P. V., Bymaster, F. P., McNamara, R. K., & Potter, W. Z. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00011 · Cited by 134
Szabo, S. T., & Blier, P. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01583.x · Cited by 125
Gartside, S. E., Hajós‐Korcsok, É., Bagdy, E., Hársing, L. G., Sharp, T., & Hajós, M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00060-9 · Cited by 109
Survey of cannabis use in patients with amyotrophic lateral sclerosis
Amtmann, D., Weydt, P., Johnson, K. L., Jensen, M. P., & Carter, G. T. (2004) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/104990910402100206 · Cited by 106
Do patients use marijuana as an antidepressant?
Gruber, A. J., Pope, H. G., & Brown, M. E. (1996) · Depression · doi:10.1002/(sici)1522-7162(1996)4:2<77::aid-depr7>3.0.co;2-c · Cited by 104
Marijuana alters the human cerebellar clock
OʼLeary, D. S., Block, R. I., Turner, B. M., Koeppel, J. A., Magnotta, V. A., Ponto, L. L. B., Watkins, G. L., Hichwa, R. D., & Andreasen, N. C. (2003) · Neuroreport · doi:10.1097/00001756-200306110-00009 · Cited by 79
Gobbi, G., & Blier, P. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.032 · Cited by 77
Self-citationCagiano, R., Cassano, T., Addolorata, C., Gaetani, S., Giustino, A., Steardo, L., Tattoli, M., Trabace, L., & Cuomo, V. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00306-2 · Cited by 30
Self-citationPlace Preference Test in Rodents
Roux, S., Froger, C., Porsolt, R. D., et al. (2003) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0915s22 · Cited by 15
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…al., 2006), and the amplification of the actions of endocannabinoids by the FAAH inhibitor URB597 was found to produce antidepressant-like effects in the mouse tailsuspension and rat forced-swim tests, without eliciting reward-related effects indicative of addictive potential (Gobbi et al., 2005).”
BackgroundNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Tzschentke, T. M. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00070.x · Cited by 1,336
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
“…of the developing brain (Buckley et al. 1998), activation of CB1 is required for the axonal growth response (Williams et al. 2003), the endocannabinoid system drives neural progenitor cell proliferation (Aguado et al. 2006), and cannabinoids actually promote neurogenesis (Berghuis et al. 2007).”
Background
Metadata
- Authors
- Gobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., Tontini, A., Tarzia, G., Mor, M., Trezza, V., Goldberg, S. R., Cuomo, V., & Piomelli, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-12-13
- Volume
- 102
- Issue
- 51
- Pages
- 18620-18625
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2103659596
- Cited by
- 673
- References
- 42
- FWCI
- 27.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.